questionText: To ask the Secretary of State for Health and Social Care, with reference to the randomised control trial study report entitled Cost utility analysis of adding abiraterone acetate plus prednisone/prednisolone to long term hormone therapy in newly diagnosed
answerText: NHS England considered abiraterone as an off-label treatment for hormone sensitive, non-metastatic prostate cancer through its clinical policy development process in 2024/25. Through this process, NHS England confirmed that there was sufficient supporting...
heading: Prostate Cancer: Hormone Treatments